Details regarding disease-modifying therapies, including chemo- and immunotherapeutic regimes for AL amyloidosis and transthyretin stabilizers for ATTR amyloidosis, are summarized in Supplementary material online, Table S1. This evidence concerns the gene TTR and AL amyloidosis.